六君子汤合丹参饮治疗气虚血瘀证冠心病临床研究

Effect of Liujunzi Decoction and Danshen Decoction on Patients with Coronary Heart Disease with Qi Deficiency and Blood Stasis Syndrome

目的分析探讨六君子汤合丹参饮对气虚血瘀证冠心病患者经皮冠状动脉介入治疗术后支架内再狭窄的影响。方法选取我院于2015年1月~2017年1月期间收治的95例气虚血瘀证冠心病患者,按照随机数字表法将所有患者随机分为对照组和治疗组两组,所有患者均采取经皮冠状动脉介入术进行治疗,其中对照组患者均给予硝酸酯类、他汀类、阿司匹林、氯吡格雷等药物进行治疗,而治疗组患者则在此基础上联合使用六君子汤合丹参饮进行治疗,所有患者均持续治疗3个月。记录两组患者治疗前后的气虚积分和证候积分、支架再狭窄率以及血瘀积分等指标,比较两组患者的临床治疗效果。结果两组患者治疗前的中医证候积分和气虚证积分、血瘀证积分等并无明显差异(均P>0.05);两组患者经过治疗后的中医证候积分和血瘀证积分均显著优于本组治疗前(均O<0.05);治疗组患者治疗后的气虚证积分显著优于本组治疗前,并且该组患者治疗后的中医证候积分和血瘀证积分均显著优于同期对照组患者(均P<0.05)。治疗组患者的再狭窄发生率为4.17%,显著低于对照组患者的19.15%(χ^2=9.374,P<0.05)。治疗组患者的总有效率为95.83%,显著高于对照组患者的87.23%(χ^2=11.444,P<0.05)。结论对气虚血瘀证冠心病患者经皮冠状动脉介入治疗术后采取六君子汤合丹参饮进行治疗能够有效改善其支架内再狭窄情况,治疗效果显著,值得在临床上加以推广运用。

Objective:To explore the effect of Liujunzi Decoction and Danshen Decoction on in-stent restenosis in patients with coronary heart disease(CHD) with Qi deficiency and blood stasis syndrome after percutaneous coronary intervention. Methods: 95 patients with Qi deficiency and blood stasis syndrome who were admitted to our hospital from January 2015 to January 2017 were randomly divided into control group and treatment group according to random number table.All patients were treated by percutaneous coronary intervention. The control group was treated with nitrate esters, statins, aspirin and clopidogrel. On this basis, the patients in the treatment group were treated with Liujunzi Decoction and Danshen Decoction. All patients were treated for 3 months. The scores of Qi deficiency and syndrome, restenosis rate of stent and blood stasis before and after treatment were recorded, and the clinical effects of the two groups were compared. Results:There was no significant difference in TCM syndrome score, Qi deficiency syndrome score and blood stasis syndrome score between the two groups before treatment(all P > 0.05);TCM syndrome score and blood stasis syndrome score of the two groups after treatment were significantly better than those before treatment(all O < 0.05);Qi deficiency syndrome score of the treatment group after treatment was significantly better than that before treatment,and TCM syndrome and blood stasis syndrome of the treatment group after treatment were significantly better than those of the control group in the same period(all P < 0.05).The restenosis rate in the treatment group was 4.17%, which was significantly lower than that in the control group(19.15%(X^2=9.374, P < 0.05). The total effective rate of the treatment group was 95.83%, which was significantly higher than 87.23% of the control group(X^2=11.444, P < 0.05). Conclusion:Liujunzi Decoction combined with Danshen Decoction can effectively improve in-stent restenosis in patients with coronary heart disease with Qi deficiency and blood stasis syndrome after percutaneous coronary intervention. The therapeutic effect is remarkable, and it is worthy of clinical application.